| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10363224 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
| US9101545 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
| US8652527 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
| US9555005 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
| US8889190 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
Qudexy Xr is owned by Upsher Smith Labs.
Qudexy Xr contains Topiramate.
Qudexy Xr has a total of 5 drug patents out of which 0 drug patents have expired.
Qudexy Xr was authorised for market use on 11 March, 2014.
Qudexy Xr is available in capsule, extended release;oral dosage forms.
Qudexy Xr can be used as treatment of seizures.
The generics of Qudexy Xr are possible to be released after 19 March, 2033.
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 11 March, 2014
Treatment: Treatment of seizures
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of QUDEXY XR before it's drug patent expiration?
More Information on Dosage
QUDEXY XR family patents
